Work

A phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with metastatic colorectal cancer receiving FOLFOX chemotherapy and bevacizumab.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.tps12125

Authors: Anne M. Noonan, Maryam B. Lustberg, Patrick Schnell, John L. Hays, Ning Jin, Laith I. Abushahin, Pannaga G. Malalur, Sameek Roychowdhury, Rifat T. Elkhatib, Huizi Chen, Salwan Al Mutar, Alex Sparreboom, Shuiying Hu

Institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, The Ohio State University Wexner Medical Center, University of Wisconsin–Madison, University of Iowa Hospitals and Clinics, University of Iowa Health Care, University of Iowa Holden Comprehensive Cancer Center, St. Jude Children's Research Hospital

Language: English

Topic: Cancer Treatment and Pharmacology

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3031307421

Cites:

Cited by: 4

Related to: 10